Novartis Emphasizes Message On Spinning Off Sandoz

Following Recent Carve-Out Of Sandoz Manufacturing Operations

Novartis has long championed the idea of making Sandoz an autonomous unit within the Swiss originator while stopping short of carving out the business altogether. Rumors continue to swirl around a potential deal, which was discussed during the recent virtual Meet Novartis Management event.

Vas Narasimhan
Novartis CEO Vas Narasimhan has been consistent in his message on Sandoz • Source: Shutterstock

Novartis continues to have no plans to spin off its Sandoz unit, amid further moves towards autonomy for the generics and biosimilars division, including the recent carve-out of Sandoz’ manufacturing operations.

More from Strategy

More from Business